AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Morgan Stanley has raised its price target for DexCom (DXCM) to $89.00, an 8.54% increase from the previous target of $82.00. The analyst maintains an "Equal-Weight" rating for the stock, indicating a neutral stance on its expected performance. The average target price for DXCM is $99.82, with an upside of 16.98% from the current price of $85.33.
Morgan Stanley has updated its price target for DexCom (DXCM), one of the leaders in glucose monitoring technology. The new price target set by analyst Patrick Wood is $89.00, up from the previous target of $82.00. This revision marks an 8.54% increase from the prior target, reflecting a more optimistic view on the future performance of DexCom. Despite the increase in the price target, Morgan Stanley maintains its "Equal-Weight" rating for (DXCM), indicating a neutral stance on the stock's expected performance relative to the broader market [1].
By continuing, I agree to the 
Market Data Terms of Service and Privacy Statement
Daily stocks & crypto headlines, free to your inbox

How might the AI Gold Rush affect the overall market trend?
What factors contributed to Reddit's significant earnings growth?
How does AI technology influence Western Digital's stock performance?
What is the current market sentiment towards tech and AI stocks?
Comments
No comments yet